Search bioRxiv⌕ Search

bioRxiv · 10.1101/2025.06.02.657388

Col6 deficiency in a zebrafish model of Bethlem myopathy leads to dysfunction of the muscle dihydropyridine receptor

Abstract

Bethlem myopathy (BM) results from mutations in genes encoding one of the three chains of collagen VI (ColVI). This muscle disease is characterized by skeletal muscle weakness and wasting worsening with age. How alteration in ColVI present outside muscle fibers in the extracellular matrix induces dysfunction within muscle fibers is still misunderstood. Here we explored intracellular Ca2+ handling properties in isolated fast skeletal muscle fibers from adult zebrafish harboring a mutation (col6a1{Delta}ex14) that is the most frequently found in BM patients. Col6a1{Delta}ex14 fish muscle exhibited progressive loss of ColVI deposition, defects in basement membrane and ColVI intracellular accumulation. By combining voltage-clamp and intracellular Ca2+ measurements on isolated fibers, we showed that voltage-dependence of intramembrane charge movements produced by the activation of CaV1.1 controlling sarcoplasmic reticulum (SR) Ca2+ release and voltage-dependence of depolarization-induced SR Ca2+ release were shifted toward negative potentials in col6a1{Delta}ex14 fish. These changes in voltage-dependence gave rise to larger SR Ca2+ leak at voltages close to resting values and to higher frequency of spontaneous SR Ca2+ release elementary events in mutant fish. Trunk muscle force and swimming performance were also found to be reduced in col6a1{Delta}ex14 fish and mis-localization of CaV1.1 subunits clusters was observed in mutant fibers t-tubules. These data indicate that ColVI deficiency in BM leads to CaV1.1 dysfunction that contributes to promote a pathogenic SR Ca2+ leak responsible for progressive muscle weakness and wasting. CaV1.1 could represent the still elusive transmembrane link allowing altered myomatrix to transduce pathogenic signals within muscle.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Idoux, R., Exbrayat-Heritier, C., Shivaraman, S., Jaque-Fernandez, F., Ducret, A., Berthier, C., Jacquemond, V., Sohm, F., bretaud, s., Ruggiero, F., ALLARD, B.. 2025-06-04. Col6 deficiency in a zebrafish model of Bethlem myopathy leads to dysfunction of the muscle dihydropyridine receptor. https://doi.org/10.1101/2025.06.02.657388

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

Negative association between nodular stromal fibrosis and large lipid droplets in human choroid plexus epithelial cells

Fibrosis is an age-related change within the human choroid plexus that is likely to affect its function negatively. We systematically analyzed nodular stromal fibrosis present in postmortem tissue from a large repository encompassing the human lifespan. Following manual annotation of sampled images from 81 specimens of choroid plexus from the atrium of the lateral ventricle, a deep learning model was trained to assess stages of fibrosis (dense, hyalinized, and mineralized) occurring in papillae across whole slide images of hematoxylin and eosin-stained sections from 204 cases. The percentage of affected papillae and the relative area of fibrosis at all three stages of severity increased with age. Affected papillae were significantly clustered across the choroid plexus, with areas of high and low fibrotic density. Choroid plexus epithelial cells (CPECs) associated with fibrotic papillae were less likely to contain large lipid droplets than were non-fibrotic papillae, as assessed by another deep learning model. Across papillae within a case, the area of each stage of fibrosis was negatively correlated with the prevalence of CPECs containing large lipid droplets. Finally, individuals displaying more nodular fibrosis had significantly fewer CPECs containing large lipid droplets. Thus, age-related nodular stromal fibrosis may negatively impact lipid storage and homeostasis for the choroid plexus and brain.

pathology↗

SilencioM: silencing connected interfering oligonucleotides against MAPT as a potential disease modifying therapeutic for tauopathies

Tauopathies are a diverse group of neurodegenerative diseases whose pathogenesis involves brain accumulation of misfolded, pathological tau (Microtubule Associated Protein Tau, MAPT). More than twenty tauopathies have been identified thus far that collectively impact millions of people worldwide, of which the most common is Alzheimer's disease (AD). Despite substantial efforts to develop drugs for tauopathies, no effective treatments currently exist, highlighting the urgent need for therapeutics to combat these prevalent and ruinous neurodegenerative diseases. Strategies that target tau are likely to have the greatest impact since tau is the proximal cause of their pathogenesis. Small interfering RNAs (siRNAs) have emerged as a powerful class of precision therapeutics that silence disease-causing genes through RNA interference with favorable safety profiles. Delivery challenges are rapidly being addressed, and siRNA-based approaches are poised to transform the therapeutic landscape of neurological diseases. In this study, we describe SilencioM (Silencing connected interfering oligonucleotides against MAPT) and show its efficacy in markedly reducing tau pathology after a single intracerebroventricular injection in PS19 mice, a mouse model of severe tauopathy. SilencioM targets human, primate, rat and mouse ortholog genes; thus, the same compound can proceed from efficacy studies to Investigational New Drug Application (IND)-enabling studies. SilencioM is simple to manufacture and is administered without encapsulation in lipid nanoparticles and without requirements for lipophilic conjugation, making it a promising candidate for further development as a novel therapeutic for tauopathies, including AD.

pathology↗

SilencioMA: A single compound that targets both MAPT and APP as a potential disease modifying therapeutic for Alzheimer's Disease

Alzheimer's Disease (AD) is the most common age-related neurodegenerative disease and the leading cause of dementia worldwide. AD pathogenesis involves aggregation of amyloid-beta (A{beta}), produced from amyloidogenic proteolytic processing of Amyloid Precursor Protein (APP), and accumulation of misfolded, pathological tau (Microtubule Associated Protein Tau, MAPT). Current efforts focus on developing disease modifying therapeutics (DMTs) against single targets: A{beta} or tau. However, DMTs that concurrently target both tau and A{beta} are likely to have the greatest impact since they target both culprits of AD pathogenesis. Here we describe the development of SilencioMA, a single compound that targets both MAPT and APP messenger RNAs (mRNAs) based on silencing connected interfering oligonucleotides against MAPT and APP. Cerebrospinal fluid (CSF) administration of SilencioMA reduces A{beta} and tau and pathology after a single intracerebroventricular injection in 5XFAD/PS19 mice, an animal model of severe amyloidosis and tauopathy. SilencioMA does not rely on lipid nanoparticles or lipophilic conjugates for CSF administration. At the same time its modular design permits conjugation of ligands that facilitate transcytosis through the blood brain barrier, allowing systemic administration. Our findings provide proof-of-concept for a strategy that targets the dual A{beta} and tau pathologies of AD, and establishes a compelling foundation for further development of SilencioMA as a next-generation DMT for AD.

pathology↗